Intelligence · Clinical Development
Pipeline search results
Programs matching “eli lilly” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 169 pipeline programs matching "eli lilly" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
I3Y-MC-JPCS
Eli Lilly Co.
Relapsed/Refractory Solid Tumors
1 trial -
I3Y-MC-JPEH
Eli Lilly Co.
Glioma
1 trial -
I5T-MC-AACI
Eli Lilly Co.
Alzheimer Disease
1 trial -
I7P-MC-DSAG
Eli Lilly Co.
Ulcerative Colitis
1 trial -
I8F-MC-GPIG
Eli Lilly Co.
Chronic Kidney Disease, CKD, Obesity, Overweight, T2D, Type 2 Diabetes
1 trial -
J1I-MC-GZBU
Eli Lilly Co.
Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
1 trial -
J1R-MC-GZFD
Eli Lilly Co.
Type 2 Diabetes
1 trial -
J1S-MC-JP04
Eli Lilly Co.
Ewings Sarcoma
1 trial -
J2R-MC-YAAD
Eli Lilly Co.
Nausea, Drug-Related Side Effects and Adverse Reactions, Vomiting, Neoplasms
1 trial -
J2S-MC-GZMR
Eli Lilly Co.
Asthma
1 trial -
J6E-MC-KWAN
Eli Lilly Co.
Ulcerative Colitis
1 trial -
LOXO-RAS-20001
Eli Lilly Co.
KRAS G12C-Mutant Advanced Solid Tumors
1 trial -
LY2157299
Eli Lilly and Company
Carcinoma, Hepatocellular
1 trial -
LY2875358, ERLOTINIB
Eli Lilly Co.
Non-Small Cell Lung Cancer
1 trial -
LY3454738
Eli Lilly and Company
Atopic Dermatitis
1 trial -
LY4268989
Eli Lilly and Company
Ulcerative Colitis (UC)
1 trial -
Mirikizumab - Intravenous (IV)
Eli Lilly and Company
Colitis, Ulcerative
1 trial -
Pirtobrutinib, Placebo tablets
Eli Lilly Co.
Immune Thrombocytopenia
1 trial -
Placebo to match LY3540378
Eli Lilly Co.
Heart Failure with Preserved Ejection Fraction, Heart Failure
1 trial -
Placebo to match LY3556050
Eli Lilly Co.
Diabetic Peripheral Neuropathy
1 trial -
Placebo to match LY3848575
Eli Lilly Co.
Neuropathic Pain; Distal Sensory Polyneuropathy
1 trial -
Ramucirumab
Eli Lilly and Company
Gastric Adenocarcinoma
1 trial -
Selpercatinib
Eli Lilly and Company
Medullary Thyroid Cancer
1 trial -
Verzenios 50 mg film-coated tablets, TAMOXIFEN
Eli Lilly Co.
Metastatic Breast Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.